Breaking Down Arrowhead Pharma: 18 Analysts Share Their Views
Providing a diverse range of perspectives from bullish to bearish, 18 analysts have published ratings on Arrowhead Pharma (NASDAQ:ARWR) in the last three months.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 9 | 5 | 4 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 2 | 1 | 0 | 0 | 0 |
| 2M Ago | 1 | 1 | 2 | 0 | 0 |
| 3M Ago | 5 | 3 | 2 | 0 | 0 |
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $77.94, along with a high estimate of $110.00 and a low estimate of $48.00. Surpassing the previous average price target of $60.67, the current average has increased by 28.47%.
Diving into Analyst Ratings: An In-Depth Exploration
An in-depth analysis of recent analyst actions unveils how financial experts perceive Arrowhead Pharma. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Patrick R. Trucchio | HC Wainwright & Co. | Maintains | Buy | $100.00 | $100.00 |
| Madison El-Saadi | B. Riley Securities | Raises | Buy | $101.00 | $61.00 |
| Patrick R. Trucchio | HC Wainwright & Co. | Raises | Buy | $100.00 | $85.00 |
| Edward Tenthoff | Piper Sandler | Raises | Overweight | $110.00 | $100.00 |
| Andrea Tan | Goldman Sachs | Raises | Neutral | $85.00 | $50.00 |
| Michael Ulz | Morgan Stanley | Raises | Equal-Weight | $81.00 | $48.00 |
| Keay Nakae | Chardan Capital | Raises | Buy | $80.00 | $60.00 |
| Edward Tenthoff | Piper Sandler | Raises | Overweight | $100.00 | $70.00 |
| Luca Issi | RBC Capital | Raises | Outperform | $80.00 | $52.00 |
| Jason Gerberry | B of A Securities | Raises | Buy | $81.00 | $62.00 |
| Patrick R. Trucchio | HC Wainwright & Co. | Raises | Buy | $85.00 | $80.00 |
| Jason Gerberry | B of A Securities | Raises | Buy | $62.00 | $42.00 |
| Keay Nakae | Chardan Capital | Maintains | Buy | $60.00 | $60.00 |
| Michael Ulz | Morgan Stanley | Raises | Equal-Weight | $48.00 | $45.00 |
| Andrea Tan | Goldman Sachs | Raises | Neutral | $48.00 | $27.00 |
| Luca Issi | RBC Capital | Raises | Outperform | $52.00 | $45.00 |
| Keay Nakae | Chardan Capital | Maintains | Buy | $60.00 | $60.00 |
| Edward Tenthoff | Piper Sandler | Raises | Overweight | $70.00 | $45.00 |
Key Insights:
- Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Arrowhead Pharma. This information offers a snapshot of how analysts perceive the current state of the company.
- Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Arrowhead Pharma compared to the broader market.
- Price Targets: Understanding forecasts, analysts offer estimates for Arrowhead Pharma's future value. Examining the current and prior targets provides insight into analysts' changing expectations.
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Arrowhead Pharma's market position. Stay informed and make well-informed decisions with our Ratings Table.
Stay up to date on Arrowhead Pharma analyst ratings.
Unveiling the Story Behind Arrowhead Pharma
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.
A Deep Dive into Arrowhead Pharma's Financials
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3M period, Arrowhead Pharma showcased positive performance, achieving a revenue growth rate of 10461.32% as of 31 December, 2025. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Arrowhead Pharma's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 11.67% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 5.96%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Arrowhead Pharma's ROA excels beyond industry benchmarks, reaching 2.06%. This signifies efficient management of assets and strong financial health.
Debt Management: Arrowhead Pharma's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.55.
What Are Analyst Ratings?
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
This article was generated by Benzinga's automated content engine and reviewed by an editor.